Search research articles
Contact Us
Filters
Showing results (31-40 of 67) with videos related to
Page
of 7
Sort By:
Advances in Therapy
|
April 3, 2004
Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes
Thomas Mundorf, Katrina A Wilcox, George W Ousler, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)
|
May 14, 2003
Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model
Mark B Abelson, Matthew J Chapin, Barry M Kapik, et al.
Advances in Experimental Medicine and Biology
|
March 5, 2003
Alternative reference values for tear film break up time in normal and dry eye populations
Mark B Abelson, George W Ousler, Lauren A Nally, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
February 14, 2013
The interblink interval in normal and dry eye subjects
Patrick R Johnston, John Rodriguez, Keith J Lane, et al.
Cornea
|
June 4, 2008
The Ocular Protection Index
George W Ousler, Katrina Wilcox Hagberg, Michael Schindelar, et al.
Allergy and Asthma Proceedings
|
December 10, 2008
A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis
Lanny J Rosenwasser, Todd Mahr, Mark B Abelson, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
February 27, 2013
Investigation of extended blinks and interblink intervals in subjects with and without dry eye
John D Rodriguez, George W Ousler, Patrick R Johnston, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
November 7, 2002
Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies
Mark B Abelson, Gregg J Berdy, Thomas Mundorf, et al.
Current Eye Research
|
December 19, 2007
Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge
Mark B Abelson, Dennis L Spangler, Arthur B Epstein, et al.
Epilepsia
|
February 21, 2009
Vigabatrin: 2008 update
L James Willmore, Mark B Abelson, Elinor Ben-Menachem, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 67) with videos related to
Sort By:
Page
of 7
Advances in Therapy
|
April 3, 2004
Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes
Thomas Mundorf, Katrina A Wilcox, George W Ousler, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)
|
May 14, 2003
Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model
Mark B Abelson, Matthew J Chapin, Barry M Kapik, et al.
Advances in Experimental Medicine and Biology
|
March 5, 2003
Alternative reference values for tear film break up time in normal and dry eye populations
Mark B Abelson, George W Ousler, Lauren A Nally, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
February 14, 2013
The interblink interval in normal and dry eye subjects
Patrick R Johnston, John Rodriguez, Keith J Lane, et al.
Cornea
|
June 4, 2008
The Ocular Protection Index
George W Ousler, Katrina Wilcox Hagberg, Michael Schindelar, et al.
Allergy and Asthma Proceedings
|
December 10, 2008
A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis
Lanny J Rosenwasser, Todd Mahr, Mark B Abelson, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
February 27, 2013
Investigation of extended blinks and interblink intervals in subjects with and without dry eye
John D Rodriguez, George W Ousler, Patrick R Johnston, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
November 7, 2002
Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies
Mark B Abelson, Gregg J Berdy, Thomas Mundorf, et al.
Current Eye Research
|
December 19, 2007
Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge
Mark B Abelson, Dennis L Spangler, Arthur B Epstein, et al.
Epilepsia
|
February 21, 2009
Vigabatrin: 2008 update
L James Willmore, Mark B Abelson, Elinor Ben-Menachem, et al.
Page
of 7